Davidson MH, Beam CA, Haffner S et al.
The University of Chicago, Chicago, IL, USA.
Arterioscler Thromb Vasc Biol 2010;30:1873–6.
Editor’s note: The present study was undertaken partly to compare the therapeutic efficacy of pioglitazone with that of glimepiride with respect to the prevention of vascular disease in patients with type 2 diabetes mellitus. This was a sub-study of the CHICAGO (Carotid Intima–Media Thickness [CIMT] in Atherosclerosis Using Pioglitazone) trial, for which the primary outcomes report has previously been published (JAMA 2006;296:2572–81). The primary endpoint, namely the magnitude of CIMT, differed in patients in the two treatment groups. The results demonstrated that 72 weeks of pioglitazone treatment slowed progression of CIMT compared with the rate of progression that was seen with glimepiride.